Navigation Links
Strengthening Forensic Toxicology in the United States: The American Board of Forensic Toxicology Response to the National Academy of Sciences Recommendations
Date:2/23/2009

nology, staffing, education, training, quality assurance and accreditation programs for laboratories performing this critical public service.

Forensic toxicology encompasses the measurement of alcohol, drugs and other toxic substances in biological specimens and interpretation of such results in a medicolegal context. The purpose of the American Board of Forensic Toxicology is to establish and enhance voluntary standards for the practice of forensic toxicology and for the examination and recognition of scientists and laboratories providing forensic toxicology services. Please visit www.ABFT.org for more information.


'/>"/>
SOURCE American Board of Forensic Toxicology
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Strengthening fluids with nanoparticles
2. The Society of Forensic Toxicologists Comments on the National Academy of Sciences Report on Strengthening Forensic Science in the United States
3. GenVault and the National Center for Forensic Science to Present Novel Technology for Room Temperature Storage of RNA
4. Orchid Cellmark Applauds Expansion of Federal Forensic DNA Identity Testing to Include All Arrestees
5. Identity Sciences Introduces a New, Fast Forensic Human I.D. Test
6. New, Fast Forensic Technology Wins R&D 100 Award
7. Isis Announces Award of Up to $8.4 Million in New Government Grants and Contracts to Its Ibis Biosciences Subsidiary for Pathogen Detection and Human Forensics
8. CFSO Calls for Roundtable to Develop National Strategy for Advancing Forensic Sciences in the United States
9. Interleukin Genetics President and Chief Scientific Officer to Present at Immunotoxicology V Conference
10. ARIUS announces cancer stem cell antibody program successfully completes first toxicology study
11. UC Berkeley Expands Molecular Toxicology Curriculum to Include GeneGos Platform

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/20/2009)...TLER TOLEDO recently announced that Dr. Dominique ...ole of Process Analytical Technology (PAT) in Gree...er 1, 2009. , (PRWEB) Nov...Analytical Technology (PAT) in Green Chemistry and... Analytical Technology (PAT) case studies will be ...
(Date:11/19/2009)...DA, Md., Nov. 19 Spherix...otechnology for diabetes therapy, and a provider o...food, supplement, biotechnology and pharmaceutical...ly reported $6.3 million registered direct placeme...of its common stock and warrants to purchase up to...
(Date:11/19/2009).../PRNewswire/ - Aegera Therapeutics Inc. announced ...zed Phase 2B study of AEG35156, a targeted antisen...le oncology indications. ,, The study, entitled...Linked Inhibitor of Apoptosis (XIAP) Antisense AEG...ne and Idarubicin in AML Following Failure of a Si...
(Date:11/18/2009)... 18 Marrone Bio Innovations (MBI),...cialization of effective and environmentally respo... has been named an IC20 company by the Investors, ...onal angel investing group. ,, Companies named ...ing results for all stakeholders, including invest...
Breaking Biology Technology:Process Analytical Technology (PAT) in Green Chemistry and Green Engineering 2Spherix Announces the Closing of $6.3 Million Registered Direct Offering 2Spherix Announces the Closing of $6.3 Million Registered Direct Offering 3Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 2Marrone Bio Innovations Named an IC20 Company 2
...icals, Inc.,a privately held biopharmaceutical com...ounced new data on its lead product, varespladib (...ual Conference in New Orleans,Louisiana. Anthera h...r the,treatment of coronary heart disease. At the ...ased new data from the Phase II PLASMA-2 study, wh...
...cut,s highest honor for technological achievement,...to Yale Professor Tso-Ping (T.P.) Ma for his pio...ut Medal of Technology is awarded by the Board of ...t Academy of Science and Engineering . It is given...Science and is designed to laud individuals "for s...
...rowth of 12.9 percent,- Full year revenue growth o... and improving profitability reflects success of s...ual financial guidance for fiscal year 2009, BATE...E: HRC ), announced unaudited financial results f...008 -- the second quarter of operations,following ...
Other Biology Technology:Anthera's Varespladib Demonstrates Significant Anti-Inflammatory Effect and LDL Reduction in Patients With Coronary Heart Disease 2Yale professor T.P. Ma awarded the Connecticut Medal of Technology 2Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 2Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 3Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 4Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 5Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 6Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 7Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 8Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 9Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 10Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 11Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 12Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 13Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 14Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 15Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 16Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 17Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 18Hill-Rom Reports Fourth Quarter Revenue Growth of 14.1 Percent to $424 Million and Adjusted Earnings Per Fully Diluted Share From Continuing Operations of $0.58, an Increase of 52.6 Percent From the Prior Year 19
(Date:11/20/2009)...Chronic obstructive pulmonary disease (COPD), a re...itis or emphysema, is the fourth leading cause of ...D and while researchers have yet to find any real ...ch Institute at The University of Western Ontario ...ques to gain new insight into the disease. , ...
(Date:11/19/2009)...It,s a naturally occurring brain chemical with an ...mouth, it can be abused or used as a date-rape dru...s have determined new routes by which 4-HB is meta...formation," said K. Michael Gibson, professor and ...ical University and a member of the research team....
(Date:11/19/2009)...MADISON This week, scientists are revealing the g...ree cereal crops. Corn, or maize, has one of the m...niversity of Wisconsin-Madison genomicist David Sc...e article in the journal Science . , "The maize...and dead-ends that have troubled would-be sequence...
Breaking Biology News(10 mins):Gaining a better picture of lung disease 2Researchers begin to decipher metabolism of sexual assault drug 2Sweet corn story begins in UW-Madison lab 2Sweet corn story begins in UW-Madison lab 3Public Health Faith Leaders Call on DC Council to Renew Funding for Successful Tobacco Prevention Programs 57025 1Public Health Faith Leaders Call on DC Council to Renew Funding for Successful Tobacco Prevention Programs 57025 2Public Health Faith Leaders Call on DC Council to Renew Funding for Successful Tobacco Prevention Programs 57025 3Public Health Faith Leaders Call on DC Council to Renew Funding for Successful Tobacco Prevention Programs 57025 4Enobia Announces Positive Clinical Results With ENB 0040 a Bone Targeted Enzyme Replacement Therapy for Hypophosphatasia 4996 1Enobia Announces Positive Clinical Results With ENB 0040 a Bone Targeted Enzyme Replacement Therapy for Hypophosphatasia 4996 2Enobia Announces Positive Clinical Results With ENB 0040 a Bone Targeted Enzyme Replacement Therapy for Hypophosphatasia 4996 3National Certification for Medical Interpreters Public Call for Final Written Pilot Exam 57018 1National Certification for Medical Interpreters Public Call for Final Written Pilot Exam 57018 2
...d a novel method for attaching small molecules, su...re used to capture large biomolecules. By varying...s, researchers can make the technique applicable t...chemical warfare agents, and environmental polluta...ntify synthetic biomolecules that recognize neurot...
...ity of Pennsylvania and Johns Hopkins University h...ommonly activated proteins in cancer is so dangero... Myc protein can stop the production of at least 1...p control which genes are turned on and off., Fur...ressed miRNAs ,into Myc-containing cancer cells su...
...th the designation of Threatened by the Committee ...SEWIC). COSEWIC is the scientific body that advise...at risk. , Since 1967, the number of chimney swi...y swifts are sooty-coloured, swallow-like birds th...rick-lined chimneys. From late April to early Octo...
Other Biology News:Biocapture surfaces produced for study of brain chemistry 2University of Pennsylvania researchers zero in on the tiniest members in the war on cancer 2
Rabbit Anti-Human Naked1 Polyclonal Antibody, Unconjugated from Cell Signaling Technology
Rabbit Anti-NF-kB p65, phospho (Ser345) Antibody, Unconjugated from Spring Bioscience
Anti-NSP-C (Neuroendocrine-Specific-Protein) Monoclonal Antibody, Unconjugated, Clone RNL-4 from CHEMICON
Rabbit Anti-Human ADAMTS-4, disintegrin-like domain Antibody, Unconjugated from CHEMICON
Biology Products: